In the phase III EV-301 trial, enfortumab vedotin (EV) has been shown to increase overall survival compared with chemotherapy in patients with metastatic urothelial carcinoma who had previously received chemotherapy and experienced disease progression after treatment with PD1 or PDL1 inhibitors. In a study published in European Urology, patient-reported outcome (PRO) analysis of health-related quality of life (HRQoL) was assessed in these patients. Specifically, changes in the validated European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-C30) from baseline to week 12 were assessed. HRQoL was maintained with EV, with the most significant improvement observed in pain reduction (P = 0.027). Results from responder analyses showed that more patients in the EV than in the chemotherapy arm reported an improvement in most of the QLQ-C30 symptom scales (10 of 15). Although the authors acknowledged some limitations of this study, including declining completion rates owing to patient death, these PRO data support the safety and efficacy outcomes in the EV-301 trial and can be used in clinical practice to complement shared decision-making.

在 III 期 EV-301 试验中，对于先前接受过化疗并在使用 PD1 或 PDL1 抑制剂治疗后出现疾病进展的转移性尿路上皮癌患者，enfortumab vedotin (EV) 已被证明与化疗相比可提高总体生存率。在欧洲泌尿学杂志上发表的一项研究中，对这些患者的健康相关生活质量 (HRQoL) 进行了患者报告结果 (PRO) 分析评估。具体来说，评估了经过验证的欧洲癌症研究和治疗组织生活质量问卷核心 30 (QLQ-C30) 从基线到第 12 周的变化。 EV 维持 HRQoL，在疼痛减轻方面观察到最显着的改善（P  = 0.027）。应答者分析结果显示，与化疗组相比，EV 组中报告大多数 QLQ-C30 症状量表改善的患者较多（15 例中的 10 例）。尽管作者承认这项研究存在一些局限性，包括由于患者死亡导致完成率下降，但这些 PRO 数据支持 EV-301 试验的安全性和有效性结果，并且可以在临床实践中用于补充共同决策。